Core Viewpoint - The domestic pharmaceutical industry is expected to experience a significant turning point in 2025, with the innovative drug sector emerging from an adjustment period to achieve a strong recovery, becoming the core growth engine of the pharmaceutical sector [5][21]. Group 1: Market Trends and Investment Dynamics - In January 2026, the CRO sector showed a clear net inflow of funds, with strong technical signals indicating a potential upward trend [5]. - The investment and financing market is recovering, with the scale of BD (Business Development) overseas reaching a historical high, alongside improvements in IND (Investigational New Drug) application and review efficiency [7]. - The first three quarters of 2025 saw the medical health primary market financing amount reach 79.53 billion yuan, a year-on-year increase of 22.4%, indicating a shift in capital allocation towards high-certainty clinical projects [12]. Group 2: Financing and BD Developments - In 2025, the total transaction amount for innovative drug BD reached 135.7 billion USD, with an upfront payment of 7 billion USD, marking a historical high [13]. - The Hong Kong stock market's financing channels have fully recovered, with IPOs and refinancing driving the market, primarily for innovative drug companies in clinical advancement stages [12]. Group 3: R&D and Regulatory Environment - The innovative drug R&D sector is witnessing a substantial recovery, with both IND application volume and approval efficiency significantly improving, leading to a steady increase in orders for the CRO industry [14][19]. - In 2025, the CDE (Center for Drug Evaluation) accepted 1,878 IND applications, a year-on-year increase of 13.34%, with class 1 innovative drug applications being the main growth driver [17]. - The NMPA (National Medical Products Administration) completed 1,897 IND application approvals in 2025, with a high approval rate for class 1 innovative drugs at 96.53% [19]. Group 4: Competitive Landscape and Future Outlook - The CRO industry is experiencing comprehensive development benefits, with leading companies leveraging their technological, scale, and compliance advantages to dominate the market [8][20]. - The global regulatory shift and digital transformation in clinical execution are expanding market space for CROs, enhancing the competitive barriers for leading firms [20]. - The recovery of the innovative drug industry presents historic development opportunities for the CRO sector, with multiple favorable factors indicating a sustained increase in industry prosperity [21].

Group 1 - The domestic pharmaceutical industry is expected to experience a significant turning point in 2025, with the innovative drug sector emerging from an adjustment period to achieve a strong recovery, becoming the core growth engine of the pharmaceutical sector [1] - In the secondary capital market, the CRO sector showed a clear net inflow of funds in January 2026, indicating a strong trend reversal signal, supported by the recovery of industry prosperity and improvement in fundamentals [1][3] - The investment and financing market is recovering, with the scale of BD going overseas reaching a historical high, alongside improvements in IND application and review efficiency, leading to a comprehensive release of demand in the clinical CRO industry [3][6] Group 2 - In the first three quarters of 2025, the financing amount in the primary healthcare market reached 79.53 billion yuan, a year-on-year increase of 22.4%, indicating a bottom reversal characteristic of "funds warming up first, projects following" [6] - The capital allocation logic has shifted from "early and small investments" to "investing in clinical and certainty," with a significant increase in the proportion of later-stage financing, which directly drives the demand for CRO and SMO services [6][7] - The total transaction amount for innovative drug BD overseas reached 135.7 billion USD in 2025, with upfront payments of 7 billion USD, marking a historical high and establishing China as the second-largest source of projects for multinational pharmaceutical companies [7] Group 3 - The number of IND applications accepted by the CDE in 2025 reached 1,878, a year-on-year increase of 13.34%, with class 1 innovative drug IND applications accounting for over 70%, indicating a shift in R&D resources towards quality [8][9] - The approval rate for class 1 innovative drug INDs reached 96.53%, and the NDA approval rate was 86.87%, reflecting significant improvements in review efficiency and approval rates [12] - The global regulatory environment is shifting towards efficiency, with the FDA focusing on enhancing R&D and review efficiency, which is expected to accelerate the demand for clinical CRO services [12][13] Group 4 - The comprehensive recovery of the innovative drug industry in 2025 presents historic development opportunities for the CRO industry, with multiple favorable factors driving the industry's prosperity [14] - It is recommended to focus on leading clinical CRO companies with digital platforms, robust compliance systems, and scale advantages, as they are expected to benefit significantly from the release of industry demand [14]